Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.
1
Study Matches
Site for Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck (PSCI# 20-106) (RTOG-1216)
To determine if the combination of atezolizumab, cisplatin, and IMRT is superior to standard cisplatin and IMRT in the HNSCC.
Pathologically (histologically or cytologically) proven diagnosis of head and neck squamous cell carcinoma Patients must have undergone gross total surgical resection of high-risk oral cavity, oropharynx (p16 Negative), larynx, or hypopharynx within 63 days prior to registration Pathologic stage III or IV HNSCC, including no distant metastases Zubrod Performance Status of 0-1 within 14 days prior to registration Adequate hepatic function
Exclusion Criteria:
Prior systemic chemotherapy or anti-EGF therapy for the study cancer; note that prior chemo for a different cancer is allowable Severe, active co-morbidity Grade 3-4 electrolyte abnormalities Prior allergic reaction to cetuximab Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields